16 results on '"Sugiura, Wataru"'
Search Results
2. Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
- Author
-
Yamamoto, Shohei, Matsuda, Kouki, Maeda, Kenji, Horii, Kumi, Okudera, Kaori, Oshiro, Yusuke, Inamura, Natsumi, Nemoto, Takashi, Takeuchi, Junko S, Li, Yunfei, Konishi, Maki, Tsuchiya, Kiyoto, Gatanaga, Hiroyuki, Oka, Shinichi, Mizoue, Tetsuya, Sugiyama, Haruhito, Aoyanagi, Nobuyoshi, Mitsuya, Hiroaki, Sugiura, Wataru, and Ohmagari, Norio
- Subjects
SARS-CoV-2 ,POST-acute COVID-19 syndrome ,BREAKTHROUGH infections ,SARS-CoV-2 Omicron variant ,CORONAVIRUS diseases ,COVID-19 - Abstract
Background Data are limited on the role of preinfection humoral immunity protection against Omicron BA.5 infection and long coronavirus disease (COVID) development. Methods We conducted nested case-control analysis among tertiary hospital staff in Tokyo who donated blood samples in June 2022 (1 month before Omicron BA.5 wave), approximately 6 months after receiving a third dose of COVID-19 mRNA vaccine. We measured live virus-neutralizing antibody titers against wild type and Omicron BA.5, and anti–receptor-binding domain (RBD) antibody titers at preinfection, and compared them between cases and propensity-matched controls. Among the breakthrough cases, we examined association between preinfection antibody titers and incidence of long COVID. Results Preinfection anti-RBD and neutralizing antibody titers were lower in cases than controls. Neutralizing titers against wild type and Omicron BA.5 were 64% (95% confidence interval [CI], 42%–77%) and 72% (95% CI, 53%–83%) lower, respectively, in cases than controls. Individuals with previous Omicron BA.1/BA.2 infections were more frequent among controls than cases (10.3% vs 0.8%), and their Omicron BA.5 neutralizing titers were 12.8-fold higher than infection-naive individuals. Among cases, preinfection antibody titers were not associated with incidence of long COVID. Conclusions Preinfection immunogenicity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may play a role in protecting against the Omicron BA.5 infection but not preventing long COVID. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Dyslipidemia and SARS‐CoV‐2 spike antibody titres after the second and third doses of the BNT162b2 vaccine among healthcare workers in Japan.
- Author
-
Islam, Zobida, Yamamoto, Shohei, Mizoue, Tetsuya, Oshiro, Yusuke, Inamura, Natsumi, Konishi, Maki, Ozeki, Mitsuru, Sugiura, Wataru, and Ohmagari, Norio
- Subjects
MEDICAL personnel ,SARS-CoV-2 ,ANTIBODY titer ,DYSLIPIDEMIA ,COVID-19 vaccines - Abstract
Objective: This study aimed to examine the sex‐associated differences in the relationship between dyslipidemia and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike immunoglobulin (Ig)G antibodies among BNT162b2 vaccine recipients. Methods: Participants were staff members (aged 21–75 years) of a medical and research institution who underwent an anti‐SARS‐CoV‐2 spike IgG antibody test after the second (n = 1872) and third doses (n = 1075) of the BNT162b2 vaccine. Dyslipidemia was defined as triglyceride level ≥150 mg/dl, high‐density lipoprotein‐cholesterol level <40 mg/dl, low‐density lipoprotein‐cholesterol level ≥140 mg/dl, or lipid‐lowering medication use. Multivariable linear regression was used to calculate the ratio of means for SARS‐CoV‐2 spike IgG titre according to dyslipidemia status. Results: The prevalence of dyslipidemia was 38.0% in men and 19.6% in women. The relationship between dyslipidemia and SARS‐CoV‐2 spike IgG titres after the second dose differed markedly by sex (P for interaction <0.001). In men, dyslipidemia was associated with significantly lower IgG titres: the ratio of means (95% confidence interval) was 0.82 (0.72–0.93). However, this association disappeared after the third dose (0.96 [0.78–1.18]). Of the dyslipidemia components, hypertriglyceridemia was inversely associated with SARS‐CoV‐2 spike IgG antibody titre after both the second and third doses (ratio of means: 0.82 [0.70–0.95] and 0.73 [0.56–0.95], respectively). In women, IgG titres did not differ according to dyslipidemia or hypertriglyceridemia status after either dose. Conclusions: These results suggest a detrimental role of hypertriglyceridemia in the humoral immune response to the BNT162b2 vaccine for COVID‐19 in men but not in women. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research centre in Tokyo after the emergence of variants.
- Author
-
Mizoue, Tetsuya, Yamamoto, Shohei, Oshiro, Yusuke, Inamura, Natsumi, Nemoto, Takashi, Horii, Kumi, Okudera, Kaori, Konishi, Maki, Ozeki, Mitsuru, Sugiyama, Haruhito, Aoyanagi, Nobuyoshi, Sugiura, Wataru, and Ohmagari, Norio
- Abstract
To describe the trend of cumulative incidence of coronavirus disease 19 (COVID-19) and undiagnosed cases over the pandemic through the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants among healthcare workers in Tokyo, we analysed data of repeated serological surveys and in-house COVID-19 registry among the staff of National Center for Global Health and Medicine. Participants were asked to donate venous blood and complete a survey questionnaire about COVID-19 diagnosis and vaccine. Positive serology was defined as being positive on Roche or Abbott assay against SARS-CoV-2 nucleocapsid protein, and cumulative infection was defined as either being seropositive or having a history of COVID-19. Cumulative infection has increased from 2.0% in June 2021 (pre-Delta) to 5.3% in December 2021 (post-Delta). After the emergence of the Omicron, it has increased substantially during 2022 (16.9% in June and 39.0% in December). As of December 2022, 30% of those who were infected in the past were not aware of their infection. Results indicate that SARS-CoV-2 infection has rapidly expanded during the Omicron-variant epidemic among healthcare workers in Tokyo and that a sizable number of infections were undiagnosed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research centre in Tokyo after the emergence of variants.
- Author
-
Mizoue, Tetsuya, Yamamoto, Shohei, Oshiro, Yusuke, Inamura, Natsumi, Nemoto, Takashi, Horii, Kumi, Okudera, Kaori, Konishi, Maki, Ozeki, Mitsuru, Sugiyama, Haruhito, Aoyanagi, Nobuyoshi, Sugiura, Wataru, and Ohmagari, Norio
- Abstract
To describe the trend of cumulative incidence of coronavirus disease 19 (COVID-19) and undiagnosed cases over the pandemic through the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants among healthcare workers in Tokyo, we analysed data of repeated serological surveys and in-house COVID-19 registry among the staff of National Center for Global Health and Medicine. Participants were asked to donate venous blood and complete a survey questionnaire about COVID-19 diagnosis and vaccine. Positive serology was defined as being positive on Roche or Abbott assay against SARS-CoV-2 nucleocapsid protein, and cumulative infection was defined as either being seropositive or having a history of COVID-19. Cumulative infection has increased from 2.0% in June 2021 (pre-Delta) to 5.3% in December 2021 (post-Delta). After the emergence of the Omicron, it has increased substantially during 2022 (16.9% in June and 39.0% in December). As of December 2022, 30% of those who were infected in the past were not aware of their infection. Results indicate that SARS-CoV-2 infection has rapidly expanded during the Omicron-variant epidemic among healthcare workers in Tokyo and that a sizable number of infections were undiagnosed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Association between γ-Glutamyl Transpeptidase and SARS-CoV-2 Spike Antibody Titers among BNT162b2 Vaccine Recipients.
- Author
-
Islam, Zobida, Yamamoto, Shohei, Mizoue, Tetsuya, Oshiro, Yusuke, Inamura, Natsumi, Nemoto, Takeshi, Konishi, Maki, Ozeki, Mitsuru, Sugiura, Wataru, and Ohmagari, Norio
- Subjects
ANTIBODY titer ,MEDICAL personnel ,SARS-CoV-2 ,HUMORAL immunity ,COVID-19 vaccines ,BINGE drinking ,ALCOHOL drinking - Abstract
Background: Increased γ-glutamyl transpeptidase (GGT) levels can deplete plasma glutathione, which in turn impairs immune regulation; however, evidence on GGT levels and post-vaccine immunogenicity is lacking. Objective: To examine the association between GGT and SARS-CoV-2 spike IgG antibodies. Methods: Participants were 1479 medical staff (aged 21 to 75 years) who received a SARS-CoV-2 antibody test after their second vaccine and whose GGT levels were measured before the vaccine rollout. Elevated and highly elevated GGT levels were defined as 51–80 and ≥81 U/L, respectively. Multivariable linear regression was used to calculate the means of SARS-CoV-2 spike IgG. Results: In a basic model, both elevated and highly elevated GGT levels were associated with significantly lower antibody titers. The ratio of mean (95% CI) was 0.83 (0.72–0.97) and 0.69 (0.57–0.84) for elevated and highly elevated GGT levels, respectively. However, these associations were largely attenuated after additional adjustment for potential confounders. An inverse association between GGT levels and antibody titers was found in women [0.70 (0.51–0.97)], normal-weight adults [0.71 (0.51–0.98)], and non-drinkers [0.73 (0.46–1.14)] but not in men, overweight adults, and alcohol drinkers. Conclusions: Circulating GGT concentrations were associated with the humoral immune response after COVID-19 vaccination, but this relationship could be ascribed to confounders such as sex, BMI, and alcohol drinking rather than GGT per se. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT).
- Author
-
Tomita, Noriko, Saito, Sho, Terada-Hirashima, Junko, Mikami, Ayako, Uemura, Yukari, Kutsuna, Satoshi, Nomoto, Hidetoshi, Fujisawa, Kyoko, Nagashima, Maki, Terada, Mari, Ashida, Shinobu, Morioka, Shinichiro, Satake, Masahiro, Hangaishi, Akira, Togano, Tomiteru, Shiratori, Katsuyuki, Takamatsu, Yuki, Maeda, Kenji, Ohmagari, Norio, and Sugiura, Wataru
- Subjects
COVID-19 ,CONVALESCENT plasma ,SARS-CoV-2 ,COVID-19 treatment ,ANTIBODY titer ,PUBLIC health - Abstract
Background: Coronavirus disease 2019 is a global public health concern. As of December 2020, the therapeutic agents approved for coronavirus disease 2019 in Japan were limited to two drugs: remdesivir, an antiviral drug, granted a Special Approval for Emergency on 7 May 2020, and dexamethasone, which has an anti-inflammatory effect. The aim of this study is to evaluate the efficacy of convalescent plasma collected from donors who recovered from coronavirus disease 2019. Methods: This is an open-label, randomized controlled trial comprising two groups: a convalescent plasma and a standard-of-care group. Plasma administered to patients with coronavirus disease 2019 randomized in the convalescent plasma group of this trial will be plasma that has been collected and stored in an associated study. Patients with a diagnosis of mild coronavirus disease 2019 will be included in this trial. The efficacy of convalescent plasma transfusion will be evaluated by comparing the convalescent plasma group to the standard-of-care group (without convalescent plasma transfusion) with respect to changes in the viral load and other measures. The primary endpoint will be time-weighted average changes in the SARS-CoV-2 virus load in nasopharyngeal swabs from day 0 to days 3 and 5. It is hypothesized that the intervention should result in a decrease in the viral load in the convalescent plasma group until day 5. This endpoint has been used as a change in viral load has and been used as an index of therapeutic effect in several previous studies. Discussion: The proposed trial has the potential to prevent patients with mild COVID-19 from developing a more severe illness. Several RCTs of convalescent plasma therapy have already been conducted in countries outside of Japan, but no conclusion has been reached with respect to the efficacy of convalescent plasma therapy, which is likely in part because of the heterogeneity of the types of target patients, interventions, and endpoints among trials. Actually, previous clinical trials on plasma therapy have shown inconsistent efficacy and are sometimes ineffective in COVID-19 patients with severe disease, which is due to unmeasured neutralizing antibody titer in the COVID-19 convalescent plasma. To improve this issue, in this study, we measure neutralizing activity of convalescent plasma before administration and provide the plasma with high neutralizing activity to the subjects. It is hoped that this study will further evidence to support the role of convalescent plasma therapy in COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Association of Impaired Fasting Glucose and Diabetes with SARS-CoV-2 Spike Antibody Titers after the BNT162b2 Vaccine among Health Care Workers in a Tertiary Hospital in Japan.
- Author
-
Islam, Zobida, Yamamoto, Shohei, Mizoue, Tetsuya, Tanaka, Akihito, Oshiro, Yusuke, Inamura, Natsumi, Konishi, Maki, Ozeki, Mitsuru, Sugiura, Wataru, and Ohmagari, Norio
- Subjects
MEDICAL personnel ,ANTIBODY titer ,TERTIARY care ,COVID-19 vaccines ,BLOOD sugar - Abstract
Background: Hyperglycemia can alter the activation of innate and acquired immunity, but epidemiological evidence linking hyperglycemia to post-vaccination immunogenicity is limited. Objective: To examine the association between SARS-CoV-2 spike antibody titers after the COVID-19 vaccine and impaired fasting glucose (IFG) and diabetes. Methods: Participants were 953 health care workers aged 21–75 years who were tested for SARS-CoV-2 spike IgG antibodies and underwent a health checkup two months after their second dose of the BNT162b2 vaccine. IFG was defined as a fasting plasma glucose (FPG) level of 100–125 mg/dL, and diabetes was defined as an FPG level ≥ 126 mg/dL or being under medical care for diabetes. Multivariable linear regression was used to calculate the ratio of the mean. Result: Spike IgG antibody titers were lower in the presence of hyperglycemia; the ratios of the means (95% CI) were 1.00, 0.79 (0.60–1.04), and 0.60 (0.42–0.87) for individuals with normoglycemia, IFG, and diabetes, respectively (p trend < 0.001). Restricted cubic spline regression analysis showed that IgG spike antibody titers decreased linearly with increasing concentrations of FPG. Conclusion: Diabetes and, to a lesser extent, IFG may be associated with poor humoral immune response after BNT162b2 vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine.
- Author
-
Khor, Seik-Soon, Omae, Yosuke, Takeuchi, Junko S., Fukunaga, Ami, Yamamoto, Shohei, Tanaka, Akihito, Matsuda, Kouki, Kimura, Moto, Maeda, Kenji, Ueda, Gohzoh, Mizoue, Tetsuya, Ujiie, Mugen, Mitsuya, Hiroaki, Ohmagari, Norio, Sugiura, Wataru, and Tokunaga, Katsushi
- Subjects
ANTIBODY formation ,COVID-19 vaccines ,IMMUNOGLOBULIN G ,SARS-CoV-2 ,PUBLIC hospitals - Abstract
BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech, New York, NY, USA), is one of the most effective COVID-19 vaccines and has been approved by more than 130 countries worldwide. However, several studies have reported that the COVID-19 vaccine shows high interpersonal variability in terms of humoral and cellular responses, such as those with respect to SARS-CoV-2 spike protein immunoglobulin (Ig)G, IgA, IgM, neutralizing antibodies, and CD4
+ and CD8+ T cells. The objective of this study is to investigate the kinetic changes in anti-SARS-CoV-2 spike IgG (IgG-S) profiles and adverse reactions and their associations with HLA profiles (HLA-A, -C, -B, -DRB1, -DQA1, -DQB1, -DPA1 and -DPB1) among 100 hospital workers from the Center Hospital of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan. DQA1*03:03:01 (p = 0.017; Odd ratio (OR) 2.80, 95%confidence interval (CI) 1.05–7.25) was significantly associated with higher IgG-S production after two doses of BNT162b2, while DQB1*06:01:01:01 (p = 0.028, OR 0.27, 95%CI 0.05–0.94) was significantly associated with IgG-S declines after two doses of BNT162b2. No HLA alleles were significantly associated with either local symptoms or fever. However, C*12:02:02 (p = 0.058; OR 0.42, 95%CI 0.15–1.16), B*52:01:01 (p = 0.031; OR 0.38, 95%CI 0.14–1.03), DQA1*03:02:01 (p = 0.028; OR 0.39, 95%CI 0.15–1.00) and DPB1*02:01:02 (p = 0.024; OR 0.45, 95%CI 0.21–0.97) appeared significantly associated with protection against systemic symptoms after two doses of BNT162b2 vaccination. Further studies with larger sample sizes are clearly warranted to determine HLA allele associations with the production and long-term sustainability of IgG-S after COVID-19 vaccination. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
10. Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan.
- Author
-
Matsunaga, Nobuaki, Hayakawa, Kayoko, Terada, Mari, Ohtsu, Hiroshi, Asai, Yusuke, Tsuzuki, Shinya, Suzuki, Setsuko, Toyoda, Ako, Suzuki, Kumiko, Endo, Mio, Fujii, Naoki, Suzuki, Michiyo, Saito, Sho, Uemura, Yukari, Shibata, Taro, Kondo, Masashi, Izumi, Kazuo, Terada-Hirashima, Junko, Mikami, Ayako, and Sugiura, Wataru
- Subjects
REPORTING of diseases ,HYPERTENSION ,CAUSES of death ,COVID-19 ,HEALTH facilities ,DIABETES ,HOSPITAL care ,SYMPTOMS ,INFECTIOUS disease transmission ,OXYGEN therapy ,DESCRIPTIVE statistics ,COMORBIDITY - Abstract
Background There is limited understanding of the characteristics of patients with coronavirus disease 2019 (COVID-19) requiring hospitalization in Japan. Methods This study included 2638 cases enrolled from 227 healthcare facilities that participated in the COVID-19 Registry Japan (COVIREGI-JP). The inclusion criteria for enrollment of a case in COVIREGI-JP are both (1) a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test and (2) inpatient treatment at a healthcare facility. Results The median age of hospitalized patients with COVID-19 was 56 years (interquartile range [IQR], 40–71 years). More than half of cases were male (58.9%, 1542/2619). Nearly 60% of the cases had close contact to confirmed or suspected cases of COVID-19. The median duration of symptoms before admission was 7 days (IQR, 4–10 days). The most common comorbidities were hypertension (15%, 396/2638) and diabetes without complications (14.2%, 374/2638). The number of nonsevere cases (68.2%, n = 1798) was twice the number of severe cases (31.8%, n = 840) at admission. The respiratory support during hospitalization includes those who received no oxygen support (61.6%, 1623/2636) followed by those who received supplemental oxygen (29.9%, 788/2636) and invasive mechanical ventilation/extracorporeal membrane oxygenation (8.5%, 225/2636). Overall, 66.9% (1762/2634) of patients were discharged home, while 7.5% (197/2634) died. Conclusions We identified the clinical epidemiological features of COVID-19 in hospitalized patients in Japan. When compared with existing inpatient studies in other countries, these results demonstrated fewer comorbidities and a trend towards lower mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
- Author
-
Maeda, Kenji, Amano, Masayuki, Uemura, Yukari, Tsuchiya, Kiyoto, Matsushima, Tomoko, Noda, Kenta, Shimizu, Yosuke, Fujiwara, Asuka, Takamatsu, Yuki, Ichikawa, Yasuko, Nishimura, Hidehiro, Kinoshita, Mari, Matsumoto, Shota, Gatanaga, Hiroyuki, Yoshimura, Kazuhisa, Oka, Shin-ichi, Mikami, Ayako, Sugiura, Wataru, Sato, Toshiyuki, and Yoshida, Tomokazu
- Subjects
ANTIBODY formation ,SARS-CoV-2 ,INVERSE relationships (Mathematics) ,COVID-19 vaccines ,IMMUNE response - Abstract
While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT
50 ; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT50 s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT50 s and ages, but no correlation seen between NT50 s and adverse effects. NT50 s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT50 s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT50 s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT50 s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan.
- Author
-
Yamamoto, Shohei, Tanaka, Akihito, Oshiro, Yusuke, Ishii, Masamichi, Ishiwari, Hironori, Konishi, Maki, Matsuda, Kouki, Ozeki, Mitsuru, Miyo, Kengo, Maeda, Kenji, Mizoue, Tetsuya, Sugiura, Wataru, Mitsuya, Hiroaki, Sugiyama, Haruhito, and Ohmagari, Norio
- Published
- 2021
- Full Text
- View/download PDF
13. Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan.
- Author
-
Tanaka, Akihito, Yamamoto, Shohei, Miyo, Kengo, Mizoue, Tetsuya, Maeda, Kenji, Sugiura, Wataru, Mitsuya, Hiroaki, Sugiyama, Haruhito, and Ohmagari, Norio
- Published
- 2021
- Full Text
- View/download PDF
14. Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.
- Author
-
Okumura, Nobumasa, Tsuzuki, Shinya, Saito, Sho, Hattori, Shin-ichiro, Takeuchi, Junko S., Saito, Tomoya, Ujiie, Mugen, Hojo, Masayuki, Iwamoto, Noriko, Sugiura, Wataru, Mitsuya, Hiroaki, and Ohmagari, Norio
- Subjects
- *
SARS-CoV-2 Omicron variant , *SARS-CoV-2 , *BREAKTHROUGH infections , *ANTIBODY titer - Abstract
The Omicron variant of severe acute respiratory syndrome coronavirus 2 has multiple amino acid mutations in its spike proteins, which may allow it to evade immunity elicited by vaccination. We examined the neutralising activity and S1-IgG titres in patients with breakthrough infections caused by the Omicron variant after two doses of vaccination. We found that neutralising activity was significantly lower for the Omicron variant than for the Wuhan strain. Two doses of vaccination might not induce sufficient neutralising activity for the Omicron variant. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
- Author
-
Yamamoto, Shohei, Fukunaga, Ami, Tanaka, Akihito, Takeuchi, Junko S., Inoue, Yosuke, Kimura, Moto, Maeda, Kenji, Ueda, Gohzoh, Mizoue, Tetsuya, Ujiie, Mugen, Sugiura, Wataru, and Ohmagari, Norio
- Subjects
- *
SARS-CoV-2 , *IMMUNOGLOBULINS , *COVID-19 , *COVID-19 vaccines - Abstract
High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine.
- Author
-
Yamamoto, Shohei, Oshiro, Yusuke, Inamura, Natsumi, Nemoto, Takashi, Horii, Kumi, Okudera, Kaori, Konishi, Maki, Ozeki, Mitsuru, Mizoue, Tetsuya, Sugiyama, Haruhito, Aoyanagi, Nobuyoshi, Sugiura, Wataru, and Ohmagari, Norio
- Subjects
- *
IMMUNOGLOBULINS , *COVID-19 vaccines , *ANTIBODY titer , *VACCINATION status , *ALCOHOL drinking , *MEDICAL research - Abstract
To examine the differences in durability and its determinants of humoral immunity following 2- and 3-dose COVID-19 vaccination. Throughout the pandemic, we evaluated the anti-spike IgG antibody titers of 2- and 3-dose mRNA vaccine recipients over time among the staff of a medical and research center in Tokyo. Linear mixed models were used to estimate trajectories of antibody titers from 14 to 180 days after the last immune-conferred event (vaccination or infection) and compare antibody waning rates across prior infection and vaccination status, and across background factors in infection-naïve participants. A total of 6901 measurements from 2964 participants (median age, 35 years; 30% male) were analyzed. Antibody waning rate (percentage per 30 days [95% CI]) was slower after 3 doses (25% [23–26]) than 2 doses (36% [35–37]). Participants with hybrid immunity (vaccination and infection) had further slower waning rates: 2-dose plus infection (16% [9–22]); 3-dose plus infection (21% [17–25]). Older age, male sex, obesity, coexisting diseases, immunosuppressant use, smoking, and alcohol drinking were associated with lower antibody titers, whereas these associations disappeared after 3 doses, except for sex (lower in female participants) and immunosuppressant use. Antibody waned slightly faster in older participants, females, and alcohol drinkers after 2 doses, whereas it did not differ after 3 doses across except sex. The 3-dose mRNA vaccine conferred higher durable antibody titers, and previous infection modestly enhanced its durability. The antibody levels at a given time point and waning speed after 2 doses differed across background factors; however, these differences mostly diminished after 3 doses. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.